Sort   by:  
 Page size 
ProteomicsCharacterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling
Kinome profiling of human basal breast cancer cell line MDA-MB-231 using CTx-0294885 or mixture of 4 broad-spectrum kinase inhibitor (Purvalanol B, SU6668, VI16832 and CTx-0294885). Kinase enrichment utilizing broad-spectrum kinase inhibitors enables the identification of large proportions of the ex...
ORGANISM(S): Homo sapiens (Human) 
2013-06-06 | PXD000239 | Pride
Mda-mb-231 Kinome profiling Ctx-0294885 Lcmsms 
ProteomicsMYC-dependent kinome in pancreatic cancer
We recently established the ERK-dependent transcriptome and phosphoproteome in KRAS-mutant pancreatic ductal adenocarcinoma (PDAC). Of 1,718 ERK-dependent genes, 143 encode transcription factors. Of 2,123 ERK-dependent phosphoproteins, 98 are transcription factors. Despite this complexity, we observ...
ORGANISM(S): Homo sapiens (Human) 
2026-01-15 | PXD061413 | Pride
Mib-ms Myc Pancreatic cancer Kinome 
ProteomicsCharacterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation
Despite significant progress, our understanding of how specific oncogenes transform cells is still limited and likely underestimates the complexity of downstream signalling events. Herein, we describe a novel, integrated approach that addresses this knowledge gap. This utilizes mass spectrometry-bas...
ORGANISM(S): Homo sapiens (Human) 
2019-01-14 | PXD010687 | Pride
Breast cancer Cancer Src Kinome 
ProteomicsDetermining MELK inhibitor specificity using MIB/MS
The key objectives of this study were to evaluate the selectivity profiles of three MELK inhibitors, 8a, HTH, and OTS, using a cell-based assay, in order to identify a highly selective inhibitor to subsequently investigate MELK function. To this end, we utilized a chemical proteomics approach called...
ORGANISM(S): Homo sapiens (Human) 
2020-01-09 | PXD016022 | Pride
Chemoproteomics Lfq Kinase enrichment 
ProteomicsIdentification and functional annotation of the Src-regulated kinome, part 2
Despite significant progress, our understanding of how specific oncogenes transform cells is still limited and likely underestimates the complexity of downstream signalling events. Herein, we describe a novel, integrated approach that addresses this knowledge gap. This utilizes mass spectrometry-bas...
ORGANISM(S): Homo sapiens (Human) 
2018-11-21 | PXD011146 | Pride
Lc-msms Kinome Phosphoproteome 
ProteomicsKinome profiling of Non-Hodgkin Lymphoma identifies Tyro3 as a therapeutic target in PEL
Non-Hodgkin lymphomas (NHL) make up the majority of lymphoma diagnoses and represent a very diverse set of malignancies. We sought to identify kinases uniquely upregulated in different NHL subtypes. Using Multiplexed Inhibitor Bead-mass spectrometry (MIB/MS), we found Tyro3 was uniquely upregulated ...
ORGANISM(S): Homo sapiens (Human) 
2019-07-11 | PXD012087 | Pride
Primary effusion lymphoma Tyro3 Non-hodgkin lymphoma Kinome profiling 
ProteomicsMIB/MS determines SCH772984 is a selective ERK1/2 inhibitor in pancreatic cancer cells
Mutational activation of the KRAS oncogene is a major genetic driver of pancreatic ductal adenocarcinoma (PDAC) growth. KRAS-dependent PDAC growth is mediated primarily through persistent activation of the RAF-MEK-ERK mitogen-activated protein kinase (MAPK) cascade, one of the most extensively studi...
ORGANISM(S): Homo sapiens (Human) 
2024-05-29 | PXD043585 | Pride
Erk Mib/ms Kinases Pancreatic cancer 
ProteomicsKinome profiling of BV2 cells treated with crizotinib or compound 32
Src homology 2 domain–containing inositol 5-phosphatase 1 (SHIP1), encoded by gene INPP5D, is a lipid phosphatase that negatively regulates immune receptor signaling in hematopoietic cells and microglia, which modulates downstream cellular proliferation, survival, and chemotaxis. Here, we report the...
ORGANISM(S): Mus musculus (Mouse) 
2026-04-03 | PXD071931 | Pride
ProteomicsKinome profiling of venetoclax-resistant wild type and NRAS-G12C MOLM-14 cells
Despite efficacy of FLT3 and BCL2 inhibition in acute myeloid leukemia (AML), relapse limits survival. Mutation status and AML monocytic differentiation are implicated in resistance. On-treatment tumor evolution may select for genetically distinct clones or shifts in differentiation not resolvable ...
ORGANISM(S): Homo sapiens (Human) 
2026-06-15 | PXD068585 | Pride
Venetoclax Gilteritinib Kinase Inhibitor Bead Aml 
ProteomicsUnique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints
RAC1P29S is the third most prevalent hotspot mutation in sun-exposed melanoma. RAC1 alterations in cancer are correlated with poor prognosis, resistance to standard chemotherapy, and insensitivity to targeted inhibitors. Although RAC1P29S mutations in melanoma and RAC1 alterations in several other c...
ORGANISM(S): Mus musculus (Mouse) 
2025-03-18 | PXD046960 | Pride
Pd-1 Rac1 Melanoma Cdk9 
Sort   by:  
 Page size